Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

VYNE Therapeutics (VYNE) EPS (Basic) (2016 - 2025)

VYNE Therapeutics' EPS (Basic) history spans 10 years, with the latest figure at -$0.13 for Q2 2025.

  • For Q2 2025, EPS (Basic) rose 40.91% year-over-year to -$0.13; the TTM value through Dec 2025 reached -$0.61, up 35.11%, while the annual FY2025 figure was -$0.62, 33.33% up from the prior year.
  • EPS (Basic) reached -$0.13 in Q2 2025 per VYNE's latest filing, up from -$0.2 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $3.94 in Q4 2023 to a low of -$14.75 in Q4 2021.
  • Average EPS (Basic) over 5 years is -$1.74, with a median of -$0.42 recorded in 2021.
  • Peak YoY movement for EPS (Basic): plummeted 2781.82% in 2021, then soared 227.1% in 2023.
  • A 5-year view of EPS (Basic) shows it stood at -$14.75 in 2021, then skyrocketed by 78.98% to -$3.1 in 2022, then surged by 227.1% to $3.94 in 2023, then plummeted by 107.11% to -$0.28 in 2024, then surged by 53.57% to -$0.13 in 2025.
  • Per Business Quant, the three most recent readings for VYNE's EPS (Basic) are -$0.13 (Q2 2025), -$0.2 (Q1 2025), and -$0.28 (Q4 2024).